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Abstract 
This study was aimed to determine the mutations and single nucleotide polymorphisms (SNPs) in exon 4 in women 
with breast cancer from Iraq. Different samples (blood, fresh tissue with blood from same patient, and formalin 
fixed paraffin embedded, FFPE). Molecular analysis of exon 4 has been studied by using PCR. It was found that 
exon 4 appeared as a single band with size 370. Single nucleotide polymorphisms (SNPs) were determined in exon 
4 ESR1 using DNA sequence. Then, nucleotide sequences of this exon were aligned with control group (healthy 
women) and with NCBI. It was detected five polymorphisms (AAA, TTT, AAA, CCG, AAA, and AAC) in exon 4 
of ESR1; all of them were novel SNPs, all types of polymorphism in exon 4 of ESR1were substitution. 
Keywords: SNPs in ESR1, ESR1 gene mutations, Breast cancer mutations  
 
1. Introduction 
Breast cancer is the most common cause of cancer death and the most common form of cancer in women with a 9% 
incidence of being diagnosed during a lifetime (1). There was increasing in the incidence rates of breast cancer 
within the last two decades, which became one of the major threats to Iraqi female health. The estrogen receptor 
(ER) plays an important role in the pathogenesis and maintenance of breast cancer, it is a ligand-inducible 
transcription factor which regulates the expression of a variety of genes including some growth factors. The cellular 
signaling of estrogens mediated through two estrogen receptors, estrogen receptor -alpha (ESR1) and estrogen 
receptor- beta (ESR2), both belonging to the nuclear receptor (NR) family of transcription factors ( 2). The ESR1 
gene is located on chromosome 6q25-27, consists of eight exons and spans more than 140 kb (3). The expression of 
ESR1 was studied as a predictive marker of treatment response, it status in breast tumors provided prognostic 
information and the primary target for endocrine therapy (4). Investigation of the molecular mechanisms of 
carcinogenesis and development of human breast cancer, the regulation of ESR1 gene expression was an important 
issue in breast cancer, and the over expression of ESR1 was an initial significant event in its genesis (5). 
 
2. Materials and Methods 
Different samples (blood, frozen tissue and blood from the same patients, and formalin fixed paraffin embedded) 
were collected from 50 women with breast cancer, with mean age 55.00 ± 10 years, 24 samples recorded with 
estrogen receptor positive used in this study for detection of mutations in ESR2.Besides, 10 samples of blood 
from healthy women with median age 45 years as control. The DNA was extracted from blood samples using the 
Reliaprep blood genomic DNA MiniPrep system from Promega, USA, fresh tissue using Maxwell® 16 Tissue 
DNA Purification Kit from Promega, USA, and formalin fixed paraffin embedded (FFPE) samples using 
ReliaPrep™ FFPE genomic DNA Miniprep from promega, USA. The extracted DNA from each sample used as 
a template for 20µl PCR reactions, and using 10µl Go Taq® Green PCR Master Mix fron Promega, USA, 1µl of 
10µm from forward primer: ACCTGTGTTTTCAGGGATACGA and reverse primer: 
GCTGCGCTTCGCATTCTTAC for exon 4 of ESR alpha (6), and 3µl of DNA template. The mixture volume 
was completed to 20µl by adding free-nuclease water. PCR process was conducted through 30 cycles with the 
following steps: denaturation for 30 sec at 95°C, annealing for 30 sec at 57°C and elongation for 40 seconds at 
72°C.In order to analyze the nucleotides sequences for all samples, DNA sequencing was performed at the 
national instrumentation center or environmental management (NICEM), using the ABI prism 3100 xl genetic 
analyzer from Applied from Biosystems, USA. 
 
3. Result and discussion 
• Amplification of exons in estrogen receptor alpha (ESR1) and beta (ESR2) genes 
The exon 4 in estrogen receptor alpha (ESR1) gene was detected by using PCR and appeared as a band size with 370 
bp (Fig. 1). 
• Polymorphisms of exon 4 in ESR1 
In exon 4 of ESR1 gene, five polymorphisms (AAA, TTT, AAA, AAA, and AAC) were detected. The type of 
polymorphisms, position and their effects on gene expression (Table 1). All mutations in exon 4 of ESR1 were 
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substitution polymorphisms that converted one base to another and then caused either no changing in the 
produced protein and this called silent polymorphism (sense mutation), or caused an exchange in the produced 
protein and this called missense mutation. 
- Sequences profile and alignment of each polymorphism in exon 4 of ESR1 
1- AAA 
The sequencing result displayed the presence of SNP G    A (Table 1). The identified SNP was missense 
mutation, it was substitution polymorphism. The common codon AGA was converted to AAA. This point 
mutation caused alteration in gene expression because of alteration in amino acid; the Arginine was converted to 
Lysine. This polymorphism found in one (4.1%) sample of FFBE. Then an alignment of nucleotides sequencing 
of exon 4 in ESR1 for women with breast cancer compared with control in NCBI center using automated 
sequencer and analyzed by BLAST data (Fig. 2). 
2- TTT 
The sequencing result illustrated the presence of SNP C     T (Table 1). The identified SNP was missense 
mutation, it was substitution polymorphism. The common codon TCT was converted to TTT. This point 
mutation caused alteration in gene expression because of revision in amino acid; the Aspartic acid was converted 
to Asparagine. This polymorphism found in 3 (13%) samples of blood. An alignment of nucleotides sequencing 
of exon 4 in ESR1 for women with breast cancer was done and compared with control in NCBI center using 
automated sequencer and analyzed by BLAST data (Fig. 3). 
3- AAA 
The sequencing result exposed the presence of SNP G     A (Table 1). The identified SNP was a silent 
polymorphism (sense mutation), it was substitution polymorphism. The common codon AAG was converted to 
AAA. This point mutation had no effect on gene expression in which the changing codon still encoded the same 
amino acid, Lysine. This polymorphism found in 1 (4.1%) sample from frozen tissue and it appeared in the blood 
of the same patient. Then nucleotides sequencing of exon 4 in ESR1 for women with breast cancer were aligned 
and compared with control in NCBI center using automated sequencer and analyzed by BLAST data (Fig. 4). 
4- AAA 
The sequencing result revealed the presence of SNP G     A (Table 1). The identified SNP was a missense 
mutation, it was substitution polymorphism. The common codon AGA was converted to AAA. This point 
mutation altered the gene expression because of changing in amino acid has happened; the Arginine was 
converted to Lysine. This polymorphism found in 6 (25%) samples; 5 samples from blood and only one samples 
from frozen tissue and also appeared in the blood sample of the same patient. The alignment of nucleotides 
sequencing of exon4 in ESR1 for women with breast cancer was done and compared with control in NCBI center 
using automated sequencer and analyzed by BLAST data (Fig. 5). 
5- AAC 
The sequencing result revealed the presence of SNP G      A (Table 1). The identified SNP was missense 
mutation, it was substitution polymorphism. The common codon GAC was converted to AAG. This point 
mutation caused alteration in gene expression because of changing in amino acid; the Aspartic acid was 
converted Asparagine. This polymorphism found in 6 (25%) samples, 5 samples from blood and one sample 
from frozen tissue as well it appeared in the blood sample from the same patient. Then an alignment of 
nucleotides sequencing of exon 4 in ESR1 for women with breast cancer compared with control in NCBI center 
using automated sequencer and analyzed by BLAST data (Fig. 6). 
The mutation and polymorphism of cancer-associated ESR1 gene found to predict tumor formation and 
prognosis (7). ERS1 was representing a surrogate marker for predicting breast cancer developing later in life (8). 
Several functionally important intronic and exonic loci of ESR1 gene polymorphisms that are associated with 
breast cancer have been examined (9). As known, estrogen receptor (ER) activation participated in development 
and progression of breast cancer because of alteration in pathways of ESR1 occurred during development of 
breast cancer and that associated with breast cancer risk and investigation (10). The function of ER was as a 
hormone dependent transcriptional regulator that plays significant role in breast cancer development (11, 12). 
Identification of a novel acquired mutation of ESR1 gene in women with metastatic breast cancer may lead to 
develop resistance to endocrine treatment. The mutations cause a conformational change, which mimics the 
conformation of activated ligand-bound receptor that lead to change the ligand-independent activity then result 
in resistance to endocrine treatment (13).The relationship between ESR1 mutations and resistance to endocrine 
therapy remains to be investigated, however, there was a significant upregulation of estrogen receptor responsive 
genes in ESR1 mutations tumors, suggesting that estrogen receptor signaling was active and may play a role in 
conferring endocrine therapy resistance (14). The mutations in ESR1 may prompt a clinician to change the 
treatment regimen from an aromatase inhibitor to an anti-estrogen, so women who developed resistance to 
aromatase inhibitors often responded to anti-estrogen therapy (15).  Moreover, the SNPs that determined in this 
study may effect copy number of ESR1 gene and may cause resistant to treatment because amplification was an 
abnormal status and normal ER protein expression (ER +ve) was requisite for response to treatment (16, 17). 
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The somatic mutation may increase sensitivity to estrogen and this may lead to increasing of proliferation at 
subphysiological level of estrogen and stimulated binding to transcription factor2 at low level of hormone (18). 
While other studies (19. 20) were showed no association between ESR1 polymorphism and breast cancer. This 
may due to the small size of samples or chose only little SNPs. 
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Notes 
Table (1): Polymorphisms in exon 4 of ESR1 gene in women with breast cancer 
No. Mutation Type Position 
Wild 
type 
codon 
Mutated 
codon 
Chang of 
amino 
acid 
Effect on 
translation 
Kind of 
mutation
No. of
patie- 
nts 
1 
G       A 
Substitution 258777 AGA AAA 
R K Missense 
mutation 
Point 
mutation 
1 
2 
C       T 
Substitution 258762 TCT TTT 
D N Missense 
mutation 
Point 
mutation 
3 
3 
G      A 
Substitution 258826 AAG AAA 
K K Sense 
mutation 
Point 
mutation 
1 
4 
G       A 
Substitution 258920 AGA AAA 
R K Missense 
mutation 
Point 
mutation 
6 
5 
G      A 
Substitution 258971 GAC AAC 
D N Missense 
mutation 
Point 
mutation 
6 
 
 
 
       
        
        
Figure (1): Amplification of exon 4 in estrogen receptor alpha set 1 primer with 370 bp. A: blood samples; 
Lanes 1-10 represent DNA from women with breast cancer, lane 11   represents DNA of negative control, 
lane 12 represents DNA from healthy subjects. B: frozen tissue samples; Lanes 1-7 represent samples 
from women with breast cancer, lane 11 represents DNA in negative control. C. FFPE samples; Lanes 1-
10 represent DNA from women with breast cancer, lane 11 represents control negative. Agarose 1.5%, 
5V/cm for 45 min, ML: molecular ladder 
A 
C 
B 
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ref|NG_008493.2| Homo sapiens estrogen receptor 1 (ESR1), RefSeqGene on chromosome6 
Length:419779   
Score                     Expect         Identities              Gaps                    Strand    
582 bits(315)          1e-162    323/325(99%)       2/325(0%)            Plus/Plus 
 
Figure (2): Alignment of exon 4 in ESR1 gene sequence of women with breast cancer using automated 
sequencer was analyzed by BLAST data, query number represents the current results while the subject 
represents the reference sequence. Blue color represents exon region, black color represented intron 
region while the single nucleotide polymorphism represents red color 
Homo sapiens estrogen receptor 1 (ESR1), RefSeqGene on chromosome 6  
Sequence ID: ref|008493.2|Length: 419779Number of Matches: 1 
Related Information 
Map Viewer-aligned genomic context 
Range 1: 258665 to 258986GenBankGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Identities Gaps Strand 
 
582bits(315) 1e-162 321/322(99%) 1/322(0%) Plus/Plus 
 
 
Figure (3): Alignment of exon 4 in ESR1 gene sequence of women with breast cancer using automated 
sequencer was analyzed by BLAST data, query number represents the current results while the subject 
represents the reference sequence. Blue color represents exon region, black color represented intron region 
while the single nucleotide polymorphism represents red color 
A   
Homo sapiens estrogen receptor 1 (ESR1), RefSeqGene on chromosome 6  
Sequence ID: ref|NG_008493.2|Length: 419779Number of Matches: 1 
Related Information 
Map Viewer-aligned genomic context 
Range 1: 258714 to 259026GenBankGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
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Score Expect Identities Gaps Strand 
544 bits(294) 8e-151 310/313(99%) 3/313(0%) Plus/Plus 
 
B  
Homo sapiens estrogen receptor 1 (ESR1), RefSeqGene on chromosome 6  
Sequence ID: ref|NG_008493.2||Length: 419779Number of Matches: 1 
Related Information 
Map Viewer-aligned genomic context 
Range 1: 258700 to 259033GenBankGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Identities Gaps Strand  
562 bits(304) 2e-156 332/337(98%) 5/337(1%) Plus/Plus 
 
 
Figure (4): Alignment of exon 4 in ESR1 gene sequence of women with breast cancer using automated 
sequencer was analyzed by BLAST data, query number represents the current results while the subject 
represents the reference sequence. Blue color represents exon region, black color represented intron region 
while the single nucleotide polymorphism represents red color; A: blood sample, B: Frozen tissue sample 
Homo sapiens estrogen receptor 1 (ESR1), RefSeqGene on chromosome 6  
Sequence ID: ref|NG_008493.2|Length: 419779Number of Matches: 1 
Related Information 
Map Viewer-aligned genomic context 
Range 1: 258700 to 259031GenBankGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Identities Gaps Strand 
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574 bits(636) 3e-160 330/332 (99%) 2/332(0%)        Plus/Plus 
 
Figure (5): Alignment of exon 4 in ESR1 gene sequence of women with breast cancer using automated 
sequencer was analyzed by BLAST data, query number represents the current results while the subject 
represents the reference sequence. Blue color represents exon region, black color represented intron region 
while the single nucleotide polymorphism represents red color 
Homo sapiens estrogen receptor 1 (ESR1), RefSeqGene on chromosome 6  
Sequence ID: ref|NG_008493.2|Length: 419779Number of Matches: 1 
Related Information 
Map Viewer-aligned genomic context 
Range 1: 258700 to 259031GenBankGraphics Next Match Previous Match  
Alignment statistics for match #1 
Score Expect Identities Gaps Strand 
574 bits(636) 3e-160 330/332 (99%) 2/332(0%) Plus/Plus 
 
Figure (6): Alignment of exon 4 in ESR1 gene sequence of women with breast cancer using automated 
sequencer was analyzed by BLAST data, query number represents the current results while the subject 
represents the reference sequence. Blue color represents exon region, black color represented intron region 
while the single nucleotide polymorphism represents red color 
 
 
 
 
 
 
 
